4SCAR19U T Cells Therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2023/11/01 20:08:59

Base Information

Drug Name4SCAR19U T Cells Therapy (Shenzhen Geno-Immune Medical Institute)
Drug Alias NameUniversal CD19-specific CAR gene-engineered T cells4SCAR19U T Cell Therapyuniversal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product,4SCAR19U cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A